

Peter Chambré has been named CEO of Cambridge Antibody Technology (Melbourn, UK), succeeding **David Chiswell**. Mr. Chambré was most recently chief operating officer of Celera Genomics Group, and previously held the post of CEO at Bepak. He will also join the board of directors at Cambridge Antibody Technology.



Peter Chambré

Alan Colman has resigned his position as research director at PPL Therapeutics (Roslin, UK) to join ES Cell International (ESI; Singapore). ESI was set up by scientists at Monash University in Australia and the National University of Singapore to develop and commercialize human embryonic stem cell research. ESI owns some of the best-characterized human stem cell lines currently in existence.

Solexa (Cambridge, UK) has announced that **Sam Eletr** has joined its board of directors and will serve as a technology and business advisor to the company. Dr. Eletr was chairman of the board of Lynx Therapeutics from 1992 to 2000, and served as CEO for much of that period. Solexa has also appointed **Tony Smith**, former vice president of research and development, UK at Amersham Biosciences, as chief technology officer.

Affymax (Palo Alto, CA) has announced the election of **R. Scott Greer** to its board of directors. Mr. Greer is co-founder, chairman, and CEO of Abgenix.

Christoph Hüls has been appointed CEO and head of the management board of proteomics start-up Protagen (Bochum, Germany). Previously, Dr. Hüls held project management, business development, and marketing and sales positions at Aventis and Novartis. Protagen also announced that co-founder **Helmut E. Meyer** has taken over the position of chief scientific officer, and co-founder **Martin Blüggel** is now chief operating officer and head of bioinformatics.

Richard L. Jackson has been appointed president and CEO of EmerGen (Salt Lake City, UT). Dr. Jackson was most recently senior vice president of research and development at Atrix Laboratories, and also served as senior vice president of discovery



research at Wyeth-Ayerst, the pharmaceutical division of American Home Products.

The Automation Partnership (Cambridge, UK) has announced that **Ron Long** has joined the company as deputy chairman. Mr. Long was CEO for Amersham Pharmacia Biotech from 1997 to 2000 and vice chairman of the life sciences group at Amersham until he retired in June 2001. He currently serves on the board of directors for Kudos Pharmaceuticals, Pharmagene, and Gyros.

Jacqueline Papkoff has been named vice president, discovery at diaDexus (S. San Francisco, CA). She joins the company from Aventis Cambridge Genomics Center (previously Hoechst-Ariad Genomics Center), where she served as vice president of cell biology and genetics and head of genomics platform technologies.

GlycoDesign (Toronto, Ontario, Canada) has announced that **Michael H. Thomas** has been appointed president, CEO, and a board member, succeeding **Jeremy Carver**, who is retiring as president and CEO. Most recently, Mr. Thomas was president and CEO of DSM Pharmaceuticals.

Dominick Vacante has joined Ceregene (San Diego, CA) as senior director of product development. Dr. Vacante was most recently director of research and development at BioReliance, and previously served on the staff of the Infectious Diseases Branch of the National Institute of Neurological Diseases and Stroke at the National Institutes of Health. Ceregene has also announced the appointment of **Brooks Ensign** as director of business development. Mr. Ensign served in the same capacity at AVIVA Biosciences.

Jesper P. Wiklund has joined DeveloGen (Göttingen, Germany) as vice president of business development. Mr. Wiklund was previously co-founder and chairman of the board of eLabsEurope, an online procurement services company. In addition, DeveloGen announced the promotion of **Cord E. Dohrmann** to vice president of research. Dr. Dohrmann joined DeveloGen in 1998 from Massachusetts General Hospital.

Surface Logix (Boston, MA) has announced the appointment of **Chi-Chi Zhu** as vice president of business development. Prior to joining the company, Ms. Zhu held the same position as part of the founding team at Celera Genomics.

